• Search

Search in Site

Industry news and analysis across pharma and medical devices PharmaDeviceNews.com

  • Home
  • Pharma & Biotech
  • Medical Devices & Diagnostics
  • Features & Analysis
  • Privacy Policy
  • About PharmaDeviceNews
  • Editorial Policy
  • Disclaimer
  • Contact Us
Home»Posts tagged with»ACC 2026

Why Kardigan’s Phase 2 tonlamarsen results matter more for acute severe hypertension than chronic blood pressure care

By Pallavi Madhiraju on March 29, 2026   Pharma & Biotech  

Why Kardigan’s Phase 2 tonlamarsen results matter more for acute severe hypertension than chronic blood pressure care

Kardigan’s tonlamarsen showed Phase 2 promise in hypertension, but can it win in acute severe hypertension next? Read the deeper analysis.

CorVista Health expands machine-learning diagnostics to INOCA with new ACC.26 poster data

By Pallavi Madhiraju on March 26, 2026   Medical Devices & Diagnostics  

CorVista Health expands machine-learning diagnostics to INOCA with new ACC.26 poster data

CorVista Health presents machine-learned non-invasive INOCA detection data at ACC.26. Analysis of what this means for cardiology and women’s heart care. Read more.

What Viz.ai’s latest hypertrophic cardiomyopathy studies reveal about the future of cardiac AI

By Pallavi Madhiraju on March 25, 2026   Medical Devices & Diagnostics  

What Viz.ai’s latest hypertrophic cardiomyopathy studies reveal about the future of cardiac AI

Viz.ai’s new HCM studies suggest AI-ECG could improve detection and follow-up. Read what this changes for cardiology workflows and adoption.

Recent Posts

  • AACR 2026: SAGA Diagnostics pushes Pathlight MRD deeper into metastatic breast and ovarian cancer
  • Agenus AACR 2026 data show immune reprogramming signal in PD-1 refractory gastroesophageal cancer
  • AACR 2026: Can Zai Lab’s zocilurtatug pelitecan change the treatment picture for small cell lung cancer brain metastases?
  • How JANX014 expands Janux Therapeutics’ tumor-activated platform strategy in prostate cancer immunotherapy
  • What Medicus Pharma Ltd.’s SkinJect application signals for Hedgehog pathway-driven cancers
  • Why Bioxodes’ adaptive trial strategy could accelerate approval timelines in stroke therapeutics
  • What Kura Oncology’s latest data reveals about resistance biology in kidney cancer
  • Can Fate Therapeutics, Inc. solve the conditioning chemotherapy problem in CAR T?
  • Could Ampligen become a late-stage pancreatic cancer breakthrough after AIM ImmunoTech’s latest clinical push?
  • What the new J-code means for Glaukos’ Epioxa launch and the future of keratoconus reimbursement
  • Molgramostim review pushed to November: what Savara’s FDA delay means for autoimmune PAP
  • What SurGenTec’s TiLink navigation clearance means for surgeons using minimally invasive SI joint fusion systems
    • About PharmaDeviceNews
    • Contact Us
    • Disclaimer
    • Editorial Policy
    • Privacy Policy
© 2026, ↑ PharmaDeviceNews
Log in - Powered by WordPress - Gabfire Themes